PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 59 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $41,000 | -71.9% | 231,900 | -4.5% | 0.02% | -71.2% |
| Q2 2022 | $146,000 | -54.4% | 242,900 | +0.2% | 0.08% | -48.1% |
| Q1 2022 | $320,000 | -51.3% | 242,473 | -3.7% | 0.15% | -46.7% |
| Q4 2021 | $657,000 | -7.9% | 251,723 | +9.8% | 0.29% | -10.5% |
| Q3 2021 | $713,000 | -16.4% | 229,223 | -0.1% | 0.32% | -8.0% |
| Q2 2021 | $853,000 | +80.0% | 229,373 | +62.6% | 0.35% | +51.9% |
| Q4 2020 | $474,000 | +45.4% | 141,025 | +51.7% | 0.23% | +15.5% |
| Q3 2020 | $326,000 | +31.5% | 92,950 | +72.2% | 0.20% | +14.9% |
| Q2 2020 | $248,000 | +115.7% | 53,974 | +55.3% | 0.17% | +65.7% |
| Q1 2020 | $115,000 | – | 34,750 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |